तुलना करने के लिए मीट्रिक्स | BIOV | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधBIOVपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −5.6x | −1.0x | −0.3x | |
PEG अनुपात | 1.46 | −0.03 | 0.00 | |
क़ीमत/बुक | 3.3x | 1.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 32.2x | 2.4x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 154.1% | 27.0% | 63.9% | |
उचित मूल्य अपसाइड | अनलॉक करें | 12.4% | 9.4% | अनलॉक करें |
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.